Kulmatycki K[au] - Search Results

Year	Number of Results
1998	1
2001	2
2005	1
2006	1
2007	2
2012	1
2013	3
2014	1
2015	2
2016	5
2017	2
2018	1
2019	1
2020	2
2021	1
2022	2
2023	1

1

Therapeutic relevance of altered cytokine expression.

Kulmatycki KM, Jamali F. Kulmatycki KM, et al. Cytokine. 2001 Apr 7;14(1):1-10. doi: 10.1006/cyto.2000.0827. Cytokine. 2001. PMID: 11298487 Review.

2

Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics.

Humphreys SC, Davis JA, Iqbal S, Kamel A, Kulmatycki K, Lao Y, Liu X, Rodgers J, Snoeys J, Vigil A, Weng Y, Wiethoff CM, Wittwer MB. Humphreys SC, et al. Among authors: kulmatycki k. Nucleic Acids Res. 2022 Jun 24;50(11):6020-6037. doi: 10.1093/nar/gkac456. Nucleic Acids Res. 2022. PMID: 35687098 Free PMC article.

3

Drug disease interactions: role of inflammatory mediators in pain and variability in analgesic drug response.

Kulmatycki KM, Jamali F. Kulmatycki KM, et al. J Pharm Pharm Sci. 2007;10(4):554-66. doi: 10.18433/j36p47. J Pharm Pharm Sci. 2007. PMID: 18261375 Free article. Review.

4

Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response.

Kulmatycki KM, Jamali F. Kulmatycki KM, et al. J Pharm Pharm Sci. 2006;9(3):292-306. J Pharm Pharm Sci. 2006. PMID: 17207413 Free article. Review.

5

Drug disease interactions: role of inflammatory mediators in disease and variability in drug response.

Kulmatycki KM, Jamali F. Kulmatycki KM, et al. J Pharm Pharm Sci. 2005 Dec 16;8(3):602-25. J Pharm Pharm Sci. 2005. PMID: 16401407 Free article. Review.

6

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).

Kazani S, Rowlands DJ, Bottoli I, Milojevic J, Alcantara J, Jones I, Kulmatycki K, Machineni S, Mostovy L, Nicholls I, Nick JA, Rowe SM, Simmonds NJ, Vegesna R, Verheijen J, Danahay H, Gosling M, Ayalavajjala PS, Salman M, Strieter R. Kazani S, et al. Among authors: kulmatycki k. J Cyst Fibros. 2021 Mar;20(2):250-256. doi: 10.1016/j.jcf.2020.11.002. Epub 2020 Dec 6. J Cyst Fibros. 2021. PMID: 33293212 Free PMC article.

7

Disposition of loratadine in healthy volunteers.

Ramanathan R, Reyderman L, Kulmatycki K, Su AD, Alvarez N, Chowdhury SK, Alton KB, Wirth MA, Clement RP, Statkevich P, Patrick JE. Ramanathan R, et al. Among authors: kulmatycki k. Xenobiotica. 2007 Jul;37(7):753-69. doi: 10.1080/00498250701463317. Xenobiotica. 2007. PMID: 17620221

8

TORC1 inhibition enhances immune function and reduces infections in the elderly.

Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, Watkins M, Shavlakadze T, Zhou W, Quinn D, Glass DJ, Klickstein LB. Mannick JB, et al. Among authors: kulmatycki k. Sci Transl Med. 2018 Jul 11;10(449):eaaq1564. doi: 10.1126/scitranslmed.aaq1564. Sci Transl Med. 2018. PMID: 29997249 Clinical Trial.

9

Pradigastat disposition in humans: in vivo and in vitro investigations.

Upthagrove A, Chen J, Meyers CD, Kulmatycki K, Bretz A, Wang L, Peng L, Palamar S, Lin M, Majumdar T, Tran P, Einolf HJ. Upthagrove A, et al. Among authors: kulmatycki k. Xenobiotica. 2017 Dec;47(12):1077-1089. doi: 10.1080/00498254.2016.1263405. Epub 2016 Dec 12. Xenobiotica. 2017. PMID: 27855567

10

Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.

He YL, Kulmatycki K, Zhang Y, Zhou W, Reynolds C, Ligueros-Saylan M, Taylor A. He YL, et al. Among authors: kulmatycki k. Int J Clin Pharmacol Ther. 2013 Sep;51(9):693-703. doi: 10.5414/CP201885. Int J Clin Pharmacol Ther. 2013. PMID: 23782585

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results